Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Pediatrix Medical (MD) over the last 11 years, with Q3 2025 value amounting to $352.2 million.

  • Pediatrix Medical's Accounts Payables changed N/A to $352.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.2 million, marking a year-over-year change of. This contributed to the annual value of $398.7 million for FY2024, which is 1365.23% up from last year.
  • Pediatrix Medical's Accounts Payables amounted to $352.2 million in Q3 2025.
  • Over the past 5 years, Pediatrix Medical's Accounts Payables peaked at $398.7 million during Q4 2024, and registered a low of $234.2 million during Q1 2025.
  • In the last 4 years, Pediatrix Medical's Accounts Payables had a median value of $327.1 million in 2023 and averaged $324.2 million.
  • As far as peak fluctuations go, Pediatrix Medical's Accounts Payables tumbled by 626.01% in 2023, and later surged by 1365.23% in 2024.
  • Pediatrix Medical's Accounts Payables (Quarter) stood at $374.2 million in 2022, then fell by 6.26% to $350.8 million in 2023, then rose by 13.65% to $398.7 million in 2024, then fell by 11.65% to $352.2 million in 2025.
  • Its last three reported values are $352.2 million in Q3 2025, $303.4 million for Q2 2025, and $234.2 million during Q1 2025.